This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Jesper Lau, Ph.D.
Vice President, Protein and Peptide Chemistry at Novo Nordisk A/S

Agenda Sessions

  • Discovery and Development of Semaglutide - The First Orally Available GLP-1 Peptide for Treatment of Type 2 Diabetes

  • Chairperson's Remarks